Budesonide is a glucocorticosteroid with a high local anti-inflammatory effect. At doses clinically equivalent to systemically acting glucocorticosteroids, budesonide gives significantly less HPA axis suppression and has a lower impact on inflammatory markers.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Budesonide is the active ingredient of these drugs:
France
Tunisia
Italy United Kingdom
Germany
Cyprus
United Kingdom
Poland
Tunisia
Hong Kong
Cyprus Hong Kong
Italy
Italy
Australia
Germany
Brazil
South Africa
Poland United Kingdom
Hong Kong Spain Tunisia
Hong Kong
New Zealand
Australia Cyprus Estonia Finland Hong Kong
Poland
Ecuador
Ecuador
Italy
Lithuania
Austria Estonia Germany Lithuania Poland
Italy
Poland
Austria
Brazil
New Zealand
Brazil
Austria Canada Cyprus Ecuador Estonia
Tunisia
Hong Kong
Italy
South Africa Spain
Austria Brazil Canada Estonia Finland
United States
Tunisia
Hong Kong Singapore
Cyprus Singapore
Estonia Lithuania Singapore
Brazil
Brazil
Ecuador
South Africa
South Africa
Spain
Austria Canada Estonia Finland Ireland
Austria Brazil Cyprus Ecuador Estonia
France
France
Ecuador
Poland
Ecuador
Brazil
Spain
Finland France Germany
United States
South Africa
Italy
Australia Austria Brazil Canada Cyprus
Canada Estonia France Germany Hong Kong
Hong Kong
Spain
Poland
New Zealand
Poland
United States
Budesonide is also found within below combination drugs:
AIRBUFO , ALENIA , BIRESP SPIROMAX , BREZTRI , BUFAR EASYHALER , BUFOLER , BUFOMIX EASYHALER , BUFORI EASYHALER , BUSALAIR , BUSTEROL , COMBIFOR , DUASTMIN , DUORESP , ENTOCORT ENEMA , FOBUMIX , FORASEQ , GIBITER , NEUMOCORT PLUS , NOTOS COMBI , PULMELIA , PULMOTON , RILAST , RILTRAVA AEROSPHERE , SYMBICORD , SYMBICORT , TRIXEO AEROSPHERE , VANNAIR , VYLAER SPIROMAX
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):